X
[{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Positive Findings From an Interim Analysis in the Phase 1\/2 trial of QR-421","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Virtual Presentation of Phase 1\/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,300.0 million","upfrontCash":"$50.0 million","newsHeadline":"ProQR Announces Axiomer\u00ae RNA Editing Licensing and Research Collaboration with Lilly","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR Announces Top-Line Results from Phase 2\/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Yarrow Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$115.0 million","newsHeadline":"ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Present its Axiomer RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Technology","graph2":"Preclinical"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$3,750.0 million","upfrontCash":"$75.0 million","newsHeadline":"Lilly and ProQR to Expand RNA Editing Collaboration","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$162.0 million","upfrontCash":"$13.7 million","newsHeadline":"ProQR Therapeutics and Laboratoires Th\u00e9a Announce Agreement for Th\u00e9a to Acquire ProQR\u2019s Sepofarsen and Ultevursen Ophthalmic Assets","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$186.3 million","upfrontCash":"$8.6 million","newsHeadline":"ProQR Therapeutics Announces Transaction Completed for Th\u00e9a to Acquire Sepofarsen and Ultevursen Ophthalmic Assets","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Rett Syndrome Research Trust","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"ProQR and Rett Syndrome Research Trust Join Forces with Axiomer\u2122 RNA Editing Collaboration","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform"}]
Find Clinical Drug Pipeline Developments & Deals by ProQR Therapeutics
Filters
Companies By Therapeutic Area
Details:
The collaboration will focus on the design and development of editing oligonucleotides (EONs) using ProQR’s Axiomer technology platform targeting the transcription factor Methyl CpG binding protein 2 (MECP2) and correcting mutations of interest.
Lead Product(s):
Undisclosed
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Rett Syndrome Research Trust
Deal Size: $1.0 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
January 05, 2024
Details:
The divestment provides Théa with ProQR's late stage ophthalmic assets, QR-110 (sepofarsen) and QR-421a (ultevursen) for patients with rare genetic eye diseases and supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform.
Lead Product(s):
Sepofarsen
Therapeutic Area: Rare Diseases and Disorders
Product Name: QR-110
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Laboratoires Thea
Deal Size: $186.3 million
Upfront Cash: $8.6 million
Deal Type: Divestment
December 08, 2023
Details:
The divestment provides Théa with ProQR's late stage ophthalmic assets, QR-110 (sepofarsen) and QR-421a (ultevursen) for patients with rare genetic eye diseases and supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform.
Lead Product(s):
Sepofarsen
Therapeutic Area: Rare Diseases and Disorders
Product Name: QR-110
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Laboratoires Thea
Deal Size: $162.0 million
Upfront Cash: $13.7 million
Deal Type: Divestment
August 01, 2023
Details:
Under the terms of the expanded agreement, Lilly will gain access to additional targets in the central nervous system and peripheral nervous system with ProQR’s Axiomer platform.
Lead Product(s):
RNA-based Therapy
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Eli Lilly
Deal Size: $3,750.0 million
Upfront Cash: $75.0 million
Deal Type: Expanded Collaboration
December 22, 2022
Details:
Following the results from the QR-110 (sepofarsen) Illuminate trial, the EMA has recommended an additional clinical trial be conducted for sepofarsen prior to submitting a Marketing Authorisation Application (MAA).
Lead Product(s):
Sepofarsen
Therapeutic Area: Rare Diseases and Disorders
Product Name: QR-110
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 11, 2022
Details:
RNA base editing technology called Axiomer, potentially new class of medicines for genetic diseases. Axiomer “Editing Oligonucleotides” mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells.
Lead Product(s):
Editing Oligonucleotides
Therapeutic Area: Technology
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 09, 2022
Details:
Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital amaurosis 10 due to the c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene.
Lead Product(s):
Sepofarsen
Therapeutic Area: Rare Diseases and Disorders
Product Name: QR-110
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 26, 2022
Details:
Axiomer editing oligonucleotides are designed to recruit an endogenously expressed RNA editing system called ADAR, which can direct change of adenosine to inosine in the RNA, and Inosine is translated as guanosine.
Lead Product(s):
RNA-based Therapeutic
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 04, 2022
Details:
The study did not meet primary endpoint nor notable secondary endpoints for QR-110 (sepofarsen) an investigational RNA therapy and, no benefit observed in either treatment arm versus sham for the treatment of CEP290-mediated LCA10.
Lead Product(s):
Sepofarsen
Therapeutic Area: Rare Diseases and Disorders
Product Name: QR-110
Highest Development Status: Phase II/ Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 11, 2022
Details:
This collaboration with Lilly, is an important validation for Axiomer® RNA editing platform of ProQR, which enables the editing of single nucleotides in RNA in a highly targeted and specific manner.
Lead Product(s):
Editing Oligonucleotides
Therapeutic Area: Genetic Disease
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Eli Lilly
Deal Size: $1,300.0 million
Upfront Cash: $50.0 million
Deal Type: Collaboration
September 08, 2021